Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 29.52 is 208% above its 5-year average of 9.58, near the high end of its 5-year range (2.86–29.52).
As of the fiscal period ended Tuesday, June 30, 2026. 112.79% above its 12-month average of 13.87.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 29.52.
CURRENT RATIO
29.52
CURRENT RATIO AVG TTM
13.87
CURRENT RATIO AVG 3Y
8.59
CURRENT RATIO AVG 5Y
9.58
CURRENT RATIO AVG 10Y
6.60
CURRENT RATIO AVG 15Y
4.88
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+112.79%
CURRENT VS 3Y AVG
+243.61%
CURRENT VS 5Y AVG
+208.13%
CURRENT VS 10Y AVG
+347.15%
CURRENT VS 15Y AVG
+504.51%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.54
median of 764 covered companies
CURRENT VS SECTOR MEDIAN
+732.64%
vs the sector median at left
Relmada Therapeutics, Inc.
Market Cap
$353.30M
Current Ratio
29.52
TTM Avg
13.87
3Y Avg
8.59
5Y Avg
9.58
Market Cap
$354.70M
Current Ratio
24.16
TTM Avg
12.00
3Y Avg
8.65
5Y Avg
7.93
Market Cap
$355.36M
Current Ratio
5.85
TTM Avg
6.36
3Y Avg
5.52
5Y Avg
8.17
Market Cap
$349.40M
Current Ratio
8.26
TTM Avg
5.36
3Y Avg
5.81
5Y Avg
4.44
Market Cap
$359.33M
Current Ratio
3.76
TTM Avg
4.71
3Y Avg
6.65
5Y Avg
8.92
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | $353.30M | 29.52 | 13.87 | 8.59 | 9.58 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $354.70M | 24.16 | 12.00 | 8.65 | 7.93 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.36M | 5.85 | 6.36 | 5.52 | 8.17 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.40M | 8.26 | 5.36 | 5.81 | 4.44 |
| Ocugen, Inc. (OCGN)vs › | $359.46M | 0.80 | 1.96 | 2.47 | 5.28 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $359.33M | 3.76 | 4.71 | 6.65 | 8.92 |
| Embecta Corp. (EMBC)vs › | $359.53M | 1.68 | 2.22 | 2.19 | 2.04 |
| Opus Genetics, Inc. (IRD)vs › | $363.54M | 12.19 | 4.83 | 10.20 | 8.85 |
| Agenus Inc. (AGEN)vs › | $333.02M | 0.34 | 0.31 | 0.55 | 0.87 |
| Canopy Growth Corporation (CGC)vs › | $374.75M | 3.04 | 3.23 | 2.34 | 4.58 |
Current Ratio
29.52
Quick Ratio
29.52
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 29.52 |
| 2026-03-31 | 18.26 |
| 2025-12-31 | 14.62 |
| 2025-09-30 | 2.86 |
| 2025-06-30 | 4.11 |
| 2025-03-31 | 5.29 |
| 2024-12-31 | 4.45 |
| 2024-09-30 | 6.89 |
| 2024-06-30 | 7.44 |
| 2024-03-31 | 6.82 |
| 2023-12-31 | 8.00 |
| 2023-09-30 | 12.95 |
| 2023-06-30 | 11.40 |
| 2023-03-31 | 13.42 |
| 2022-12-31 | 12.26 |
| 2022-09-30 | 9.01 |
| 2022-06-30 | 11.40 |
| 2022-03-31 | 14.65 |
| 2021-12-31 | 14.83 |
| 2021-09-30 | 4.98 |
| 2021-06-30 | 7.95 |
| 2021-03-31 | 8.16 |
| 2020-12-31 | 9.37 |
| 2020-09-30 | 37.02 |
| 2020-06-30 | 57.78 |
| 2020-03-31 | 50.97 |
| 2019-12-31 | 80.21 |
| 2019-09-30 | 3.27 |
| 2019-06-30 | 3.83 |
| 2019-03-31 | 1.09 |
| 2018-12-31 | 1.63 |
| 2018-09-30 | 0.18 |
| 2018-06-30 | 0.46 |
| 2018-03-31 | 0.81 |
| 2017-12-31 | 1.36 |
| 2017-09-30 | 1.52 |
| 2017-06-30 | 1.80 |
| 2017-03-31 | 2.64 |
| 2016-12-31 | 3.75 |
| 2016-09-30 | 3.15 |
| 2016-06-30 | 3.04 |
| 2016-03-31 | 4.90 |
| 2015-12-31 | 3.27 |
| 2015-09-30 | 3.02 |
| 2015-06-30 | 1.54 |
| 2015-03-31 | 1.10 |
| 2014-12-31 | 1.17 |
| 2014-09-30 | 0.57 |
| 2014-06-30 | 0.96 |
| 2014-02-28 | 0.21 |
| 2013-11-30 | 0.27 |
| 2013-08-31 | 0.55 |
| 2013-05-31 | 0.12 |
| 2013-02-28 | 0.85 |
| 2012-11-30 | 0.00 |
| 2012-08-31 | 2.62 |
| 2012-05-31 | 0.00 |
| 2012-02-29 | 0.00 |
